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CHAPTER I 
 
INTRODUCTION 
 
All functions performed by the human body must simultaneously happen in each 
cell comprising that body.  On a large scale, these processes are undertaken by groups of 
cells organized into organ systems.  But on a much smaller scale, each cell is executing 
all life functions. One of these processes, growth, includes all of the tasks necessary to 
regulate size, function and state of the cell.  Growth is driven by several factors including 
the interaction between cell surface receptors and their downstream signaling. For this 
discussion though, the preeminent level of regulation happens through the cell cycle, a 
procedure by which cells must pass checkpoints or meet established requirements in 
order to continue to grow and replicate. Viruses, living as parasites, hijack and alter cell 
processes and regulatory pathways for their own growth and proliferation even if 
detrimental to the cell.  Any interference in the cell cycle, whether through genetic 
mutations or in this case a virus, is the principle definition of cancer--deregulated growth 
(Ewen et al. 1993).   The following work will present established dogma on cell cycle and 
transcriptional regulation in the context of Primary Effusion Lymphoma (PEL) caused by 
Kaposi’s sarcoma-associated herpesvirus (KSHV), particularly in the latent phase, with a 
focus on the role of the viral gene product, Kaposi’s sarcoma-associated herpesvirus-
encoded cyclin (K-cyclin).   
 
Objective 
The goal of this work is to characterize the interaction and functionality of the 
interaction between Kaposi’s sarcoma herpesvirus encoded-cyclin (K-cyclin) and 
latency-associated nuclear antigen.  More generally, a better understanding of the 
interaction of viral gene products through these particular related proteins is important, as 
we strive to understand the basis of its transforming properties. By examining the 
structure, function and cooperation of K-cyclin and LANA, we hope to better understand 
the role that viral genes play in oncogenesis and pathogenesis.  There is limited data to 
support the role of both proteins in replication with more available to support LANA’s 
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role in episomal maintenance.  Based on the literature and unpublished data from the 
Browning Lab, we believe that the interaction between these viral gene products and a 
potential affect on transcription could explain a previously unknown association between 
these proteins. 
 
Kaposi’s Sarcoma-Associated Herpesvirus 
The causative agent of Kaposi’s sarcoma (KS), multicentric Castlemen’s disease 
(MCD) and PEL is KSHV, also called human herpesvirus 8 (HHV-8) (Chang et al. 
1994).  This γ-2-herpesvirus, that like the other γ-herpesviruses--murine herpesvirus 68, 
herpesvirus samiri and Epstein-Barr virus (EBV) can contribute to cancer. By hijacking 
the host cell's own established systems, KSHV will address its goals of advancing host 
cell proliferation, blocking apoptosis and ensuring viral progeny.  While the viral proteins 
can interact and phosphorylate pRb with the D-type cyclin dependent kinase (cdk) partner 
cdk6, they are not susceptible to the cdk inhibitors.  This interruption in cell cycle 
regulation plays a role in its oncogenic potential (Chang et al. 1996, Cesarman et al. 
1996, Moore et al. 1996, Swanton et al. 1997). 
 
KSHV genome 
The principal infected cell in KS tumors is the spindle cell, an unusual one that 
expresses surface markers of both endothelial cells and macrophages (Ensoli et al. 2001). 
The majority of KS-associated spindle cells, although containing a low copy number, are 
infected with KSHV and express latent proteins; but, a few of the associated 
inflammatory cells appear to be infected as well. As a result, the KSHV genome present 
in spindle cells is thought to be at the heart of viral pathogenesis (Davis et al. 1997). Most 
of these latently infected cells do not secrete virus. Small subsets of them express lytic 
genes (Staskus et al. 1997), and electron microscopy confirms that these cells are 
producing viral progeny (Orenstein et al. 1997). Preliminary molecular epidemiologic 
studies of virus derived from clinical samples reveal that subtypes cluster by geographic 
region and that virus repeatedly detected from the same individual does not vary (Zong et 
al. 1999, 2002). Superinfection with more than one strain of HHV-8, however, has also 
been reported (Beyari et al. 2003). 
 3
The KSHV genome is packaged into an icosahedral capsid of approximately 1200 
angstroms (Trus et al. 2001) with a typical herpesvirus envelope and tegument. The 
linearized genome is double-stranded DNA with approximately 145 kilobases of unique 
coding region and 801 basepairs of GC rich sequence at either end called the terminal 
repeats (TR) (Figure 1, Russo et al. 1996).   More than 80 open reading frames (ORFs) 
have been identified and are numbered consecutively from the left-hand side of the 
genome, with the genus-conserved regions designated with ORF and the frames unique to 
HHV-8 named K1 through K15.  Methylation of the episome likely plays a role in 
maintaining latency, a phase identified by the lack of production of viral progeny (Chen 
et al. 2001). Although the precise sequence of events leading to the activation of lytic 
replication has not been defined, the gene product of ORF50 is necessary and sufficient 
to initiate the lytic phase of the HHV-8 life cycle (Gradoville et al. 2000, Deng et al. 
2002). 
 
Life Cycle: Lytic and Latent Phases 
Gene expression can be characterized into groups based on function and the order 
of expression. The most definitive classes of proteins are those made in the latent and 
lytic phases of the host cell cycle. When the host cell shifts from lytic to latent phase, a 
number of herpesviral homolog genes become active at the same time that other genes 
turn dormant. For example, one of the first genes to become active upon this shift is ORF 
50, a homolog of the EBV protein Rta, whose promoter can be activated by the KSHV 
virion alone (Lu et al. 2005).   
The lytic phase of KSHV is the time of the life cycle when the host cell is 
producing mature virions able to infect other cells.  In order for this to happen, the virus 
must regulate which genes are expressed and their order.  The immediate early 
transactivators are those turned on first during the lytic phase. They are primarily 
responsible for regulation of gene expression and include ORF50 (RTA), K8 (K bZIP or 
Zta), and ORF 57, a regulator of post-translational modifications.  Secondly, early genes 
are made and responsible for viral DNA replication and its processing.  For example, 
viral thymidylate synthase, which is involved in nucleotide biosynthesis is transcribed at 
this time, as well as viral chemokines and chemokine receptors like viral-macrophage 
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inflammatory protein (v-MIP), viral-G coupled protein receptor (v-GCPR). The last or 
late genes are those involved in maturation and packaging of the virus like small viral 
capsid antigen (sVCA) encoded by ORF65 and (Sun et al. 1999, Zhu et al. 1999, Jenner 
et al. 2001, Paulose-Murphy et al. 2001). 
 
 
Figure 1. Kaposi’s Sarcoma-Associate Herpesvirus’ Genome Encodes Three Latent Proteins 
Regulated by the Same Promoter.  Kaposi’s sarcoma-associatedd herpesvirus (KSHV) is a 
DNA virus that infects human B cells. The KSHV genome is approximately 140 kilobases in 
length and attaches itself to genomic DNA as an episome, remaining circular and not integrated.  
The magnified section of DNA, shown here, encodes for three latent proteins regulated by the 
same promoter.  ORF71, latency-associated nuclear antigen (LANA), ORF 72, viral-encoded 
cyclin homolog, K-cyclin, and viral-FLICE like inhibitory protein, v-FLIP are made on one 
transcript and then are spliced during processing for translation. 
 
 
Latent Gene Products 
The best characterized latent genes are clustered together and play integral roles 
in overriding normal cell cycle checkpoints, anchoring and directing the processing of the 
viral episome and blocking apoptosis. These three genes, ORF72 encoding K-cyclin, 
ORF73 encoding LANA, and ORF71 encoding viral Fas-ligand interleukin-1B-
converting enzyme inhibitory protein, or v-FLIP, are all regulated by the same promoter, 
made as one message and the proteins spliced out to expression (Figure 1, Hu et al. 
2005). K-cyclin, a cyclin D2 mimic, is the primary agent of cell cycle deregulation (Child 
140 kb
122144 122710 123808 127296123566
TR TR
KSHV genome
ORF73 ORF 72ORF71 
v-Flip K-cyclin LANA 
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et al. 2001).  LANA plays an integral role in establishing and maintaining the episome in 
the host cell (Ballestas et al. 1999).  vFLIP protects cells from apoptosis by blocking the 
activation of the Fas death receptor pathway (Irmler et al. 1997). This inhibits the cell 
from tagging itself for termination by cytotoxic T-cells, even if an internal problem is 
identified (Djerbi et al. 1999).  v-IL-6, v-Bcl-2, v-IRF are cellular homologs that promote 
cell proliferation and growth, induce angiogenesis, support cell survival and evade the 
natural immune response (Tanaka et al. 1996, Arvanitakis et al. 1997, Cheng et al. 1997, 
Gao et al. 1997).  Virally infected cells spend the majority of their life cycle in latency, 
even when the viral genome itself is no longer present and so these genes are expressed in 
KS spindle and PEL cells and so are directly related to the cell’s physical characteristics 
(Sun et al. 1999).   
 
NF-κB Activation in KSHV infected Cells 
NF-κB is a key pathway in the establishment of latency in KSHV infected B-cells 
(Krug et al. 2007). Therefore, it is not surprising that this pathway would be a vital target 
for one or more viral genes.  The fact that all KSHV infected cell lines have the same 
level of NF-κB activation shows its importance in pathogenesis (Keller et al. 2000).  
These studies also suggest that the activation’s source is similar in both cell lines and 
spindle cells.  Because NF-κB regulates the expression of several anti-apoptotic genes 
like Bcl-2 and Bcl-xL, it is a common target of virally infected cells (Grimm et al. 1996, 
Tsukahara et al.1999).  In Epstein-Barr Virus (EBV), latent membrane protein-1 (LMP-1) 
is the activator, in human T-cell leukemia virus type 1 (HTLV-1), tax is the culprit 
(Chaudhary et al. 1999, Djerbi et al. 1999, Tsukahara et al. 1999, Huang et al. 2001).  In 
KSHV, v-FLIP has been shown to be a more efficient activator of NF-κB than cellular 
FLIP and is responsible for seventy percent of NF-κB in KSHV cell lines (Chaudhary et 
al. 1999, Guasparri et al. 2004).  v-FLIP’s mechanism involves using its two DED 
domains to block the interaction between Fas-associated protein with death domain 
(FADD) and pro-caspases 8 and 10, an interaction required for the signaling cascade used 
to trigger apoptosis (Thome et al. 1997).  v-FLIP can also activate IκK complexes which 
can result in IL-6 expression.  When v-FLIP was suppressed, one hundred percent of 
 6
activating protein-1 (AP-1) activity and seventy percent of NF-κB associated with IL-6 
was abolished (Djerbi et al. 1999, Liu et al. 2002, Field et al. 2003, An et al. 2003).  
Although there was some evidence to support that K1, v-GPCR and K15 played a 
central part in NF-κB activation in latency, Guasparri et al. eliminated that possibility by 
showing that v-FLIP’s action is essential for the survival of infected lymphoma cells 
(Samananeigo et al. 2000, Pati et al. 2001, Guasparri et al. 2004).  This work reiterates 
how viral proteins have exploited NF-κB’s action for their own purposes in this case to 
ensure their own survival. Discussion of KSHV gene products from this point will 
revolve around two of the clustered latent genes, LANA and K-cyclin which will be 
shown to associate in the G1 phase of the cell cycle.   
 
Latent Associated Nuclear Antigen 
Latent Associated Nuclear Antigen (LANA) is a multifunctional protein that acts 
as a viral liaison for episomal maintenance, transcription, cell cycle regulation and DNA 
replication.  The protein is expressed as a part of a 5.32 kilobase transcript made in the 
latent phase of the virus and spliced to make three different proteins (Figure 1). ORF71 
makes viral FLICE-like inhibitory protein (v-FLIP), ORF72 makes viral cyclin D mimic 
(K-cyclin), and ORF73 makes LANA (Dittmer et al. 1998, Sun et al. 1999, Low et al. 
2001, Kellam et al. 1997).   Although the 1162 amino acid protein has a theoretical 
molecular mass of 135-140 kilodaltons, it actually migrates in an SDS-polyacrylamide 
gel (PAGE) between 220-239 kilodaltons (Renne et al. 1996). The N-terminal domain of 
LANA includes a nuclear localization signal (NLS), a chromosome binding and proline 
rich region all involved in tethering the protein to host chromatin. The highly acidic 
central region acts as a flexible linker region made up of repeats rich in glutamine and 
glutemic acid (Russo et al. 1996).  The hydrophobic C-terminal domain contains a 
leucine zipper motif that has been shown to physically bind one LANA molecule to p53, 
pRb, histone H1, CREB/ATF, the LANA promoter, and itself (Figure 2, Fribourg et al. 
1999, Gao et al. 1999, Lim et al. 2000, Radkov et al. 2000, Barbera et al. 2004, Jeong et 
al. 2004, Wong et al. 2005, Cai et al. 2006).  In this case, the structure/function 
relationship is essential as it facilitates the protein's tethering ability.  
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Figure 2. K-cyclin, LANA and p300 Protein Structure.  (A). K-cyclin is a viral homolog of 
cellular D-type cyclins.  It contains two alpha-helical domains, the first being the signature cyclin 
box, where cellular cyclins are known to interact with cyclin dependent kinases (cdks). The 
second alpha-helical domain is responsible for binding to transcriptional machinery like TFIIB. 
The protein docking site, MRAIL, which may play a role in substrate selection is located at the 
N-terminus beginning at position 50. (B). LANA is a nuclear protein known to play a significant 
role in episomal maintenance, DNA replication and transcription. Episomal maintenance is 
mediated by the chromosome binding domain (CBD) while DNA binding, dimerization and other 
protein binding by the C-terminal domain.  The center acidic region acts as a flexible linker 
region to connect the protein, important for LANA’s tethering of the episome to genomic DNA. 
(C). p300 is a transcriptional co-activator known to be present during NF-κB activation.  The 
protein can bind to several other transcriptional regulators like p53, c-Jun, and c-Myc through its 
CRB binding domain, bromodomain and glutamine-rich regions.  p300’s activation ability comes 
from its histone acetyltransferase (HAT) activity.  This allows p300 to acetylate chromatin 
binding histones and relax the DNA for transcriptional activity. 
 
Episomal Maintenance 
LANA is required for the replication and maintenance of the viral genome.  
Because the genome never inserts itself into the cellular DNA, it must attach itself in a 
particular way to ensure its replication and succession to daughter cells (Ballestas et al. 
1999, Ballestas et al. 2001, Cotter et al. 2001, Grundhoff et al. 2003, Lim et al. 2004).  
LANA does this by using its N-terminus to bind to the nucleosome, in particular histone 
1     2     3     4       5 1’    2’    3’     4’     5’ 
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DNA Binding  
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H1, to achieve long-term persistence probably in concert with other cellular proteins 
(Shinohara et al. 2002).  On the other end, the C-terminal part of LANA, specifically 
amino acids 884-1089, can bind to each other and form a dimer, while amino acids 996-
1139 bind directly to the TR region of the viral DNA (Schwam et al. 2000).  The two 
LANA binding sites (LBS1/2) are 22 basepairs apart in the TR region and both contribute 
to repress transcription and facilitate DNA replication (Garber et al. 2002).   When a 
virus was created without LANA (BAC36 ΔLANA), the episome was not maintained and 
the cells were virus free in two weeks (Ye et al. 2004).  In addition, when small hairpin 
RNA was used to knock down expression of the whole latent cluster of proteins, there 
were reduced numbers of episomes per cell.  A deletion of amino acids 5-22 of the 
protein were sufficient to ablate episomal maintenance but could be re-established with 
the addition of the histone H1 protein (Shinohara et al. 2002).  
 
DNA Replication 
While the literature clearly supports LANA's role in episomal maintenance, 
several groups have investigated a role in DNA replication separately.  The origin 
replication complex proteins (Orcs 1-6) must assemble in the proper order to begin the 
process and subsequent cascade of cdc and MDM proteins required for licensing 
initiation of DNA replication (Xua et al. 1998).  EBNA1, another viral protein involved 
in DNA replication, sets a clear precedent for this role as it and LANA both co-
immunoprecipitate from nuclear extracts with members of the ORC protein complex 
(Dhar et al. 2001, Lim et al. 2002). In LANA, this association to the ORC proteins occurs 
through the C-termini.  The section of DNA is the same region containing the LANA 
binding sites implicated in episomal maintenance, noting that a single LBS is sufficient to 
support plasmid replication in transient assays (Hu et al. 2002).   Furthermore, LANA can 
induce a strong bend in the DNA.  This bend is the greatest when both binding sites are 
occupied, turning it 110 degrees, but either binding site alone will open the DNA toward 
the major groove 57 degrees.  This reordering of the DNA could facilitate the assembly 
of the pre-replication complex or its licensing factors (Wong et al. 2005).   
 
 9
Transcriptional Regulation 
While its primary role involves episomal maintenance with recent work 
supporting its role in DNA replication, LANA also functions as a transcriptional 
regulator.  While it can activate EBV and human immunodefiency virus (HIV) 
promoters, its mechanisms of activation have been characterized using a variety of 
cellular and viral promoters, including its own (Groves et al. 2001, Lim et al. 2001, 
Renne et al. 2001, Garber et al. 2002, Verma et al. 2004). The LANA promoter, which 
contains a DPE and TATA box, is defined as the region between +11 and +271 upstream 
of the mRNA start site. This structure is rare in eukaryotes, in that most promoters have 
either one or the other site as their function is usually the same.  In this case, neither site 
is sufficient to support the basic transcriptional machinery and so needs other 
downstream factors.  The GC box/Sp1 binding site at -29 is additionally required as 
additional support for LANA regulation of its own promoter (Garber et al. 2001, Jeong et 
al. 2004). In human telomerase reverse transcriptase (hTERT) activation, LANA does not 
bind to DNA, but instead interacts with the Sp1 protein and acts as a co-activator (An et 
al. 2002).  In a similar way, LANA acts as a transcriptional co-activator of c-Jun and 
specifically binds to the AP-1 response element (RE) to induce IL-6 transcription (An et 
al. 2002). This may be significant because IL-6 is NF-κB-dependent and was reported to 
be an essential growth factor for the KSHV related diseases (An et al. 2004).   LANA is 
also known to stabilize β-catenin in the cytoplasm by binding to GSK-3β, interact with 
STAT3 and modulate TGF-β signaling and associate with Jkappa, a Notch pathway 
protein, to repress the viral protein, RTA (Fujimoro et al. 2005, Lu et al. 2005, Muromoto 
et al. 2006). This repression in turn causes a "de-repression" of LANA, as RTA limits the 
activity of the LANA promoter (Jeong et al. 2004). When LANA is tethered to 
constitutively active promoters, it interacts with itself, heteroprotein 1, mSin3, 
CREB/ATF and CREB binding protein as well as CIR to inhibit constitutively active 
promoters in vitro (Lim et al. 2003).   
 
Cell Cycle Regulation 
These transcriptional properties also relate to the cell cycle as LANA can 
modulate p53 expression as well as binding directly to pRb and releasing the E2F 
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transcription factors (Figure 3, Fribourg et al. 2000).  These cells are protected from p16 
induced cell cycle arrest by LANA’s interaction with BRD4 and its subsequent activation 
of the cyclin E promoter (An et al. 2005, Viejo-Borbolla et al. 2005, Ottinger et al. 2006).  
 
 
Figure 3. K-cyclin is Constituitively Active throughout the Cell Cycle. The cell cycle is tightly 
regulated by cyclin proteins. These proteins are must be activated by the cyclin activating kinase 
(CAK), and are present only during certain phases when they bind to certain cyclin dependent 
kinases (cdks) and have their action.   When their work is complete, they can be repressed by cdk 
inhibitors and are immediately targeted for degradation. Progression through the cell cycle is 
based on the phosphorylation and de-phosphorylation of the pRb protein by the cyclins.  This 
checkpoint verifies the complete working order of the cell before it is allowed to replicate and 
divide.  If the cell cannot pass the checkpoint or is insuitable in replication, it will be targeted for 
apoptosis.  In KSHV infected cells, K-cyclin dysregulates this system.  K-cyclin does not need 
CAK phosphorylation to become active.  It can bind to cdks 2, 4 and 6, and act in different phases 
of the cell cycle.  K-cyclin can also phosphorylate Rb and evade this cell cycle checkpoint.  
Additionally, K-cyclin/cdk6 complexes are constitutively active throughout the cell cycle and can 
give unsuitable cells license to replicate. 
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In this way, LANA has cemented its role as a fundamental aspect of KSHV latency 
through its role of modulating several cell and viral processes including episomal 
maintenance, DNA replication, transcription, and cell cycle regulation.    
 
Kaposi's Sarcoma Associated Herpesvirus Encoded-Cyclin, K-cyclin 
The primary function of the cell is to grow and replicate in an orderly fashion.  
This work happens under several strictly regulated layers united under the overarching 
theory of the cell cycle.  It divides the time between the formation of two daughter cells 
called mitosis and the next set of daughter cells.  Therefore, it is the acknowledgement of 
the mitosis signal and preparation for that mitosis.  Transitions between phases of the cell 
cycle are regulated by the activity of cyclin proteins and cyclin dependent kinases (cdks).   
Cyclins D/E mediate the progression from G1 to S phase.  Cyclins A/B mediate the 
transition between S to G2 phases and then from G2 to the mitosis or M phase.  These 
cyclins bind to their appropriate cdk partner, cdks 1, with cyclin B, cdk 2, with cyclin E 
and cdks 4, and 6 with D-type cyclins (Figure 3, Zhang et al. 2000, Wu et al. 2001).  
 
Cell Cycle Regulation 
The major responsibility of cyclin D/cdk complexes are to activate the cell cycle 
checkpoint between G1 and S phases, with cyclin B/cdc2 complexes responsible for 
stimulation of dephosphorylation of pRb for the exit from mitosis. This checkpoint is the 
hyperphosphorylation and subsequent disassociation of pRb and its binding partner E2F.  
When pRb is hypophosphorylated, it directly represses the cyclin A promoter, thereby 
blocking S-phase progression (Ewen et al. 1993, Zhang et al. 2000).  When E2F is 
released, cyclin A expression is allowed.  The binding also directly blocks the active site 
of E2F and represses its transcriptional activity (Helin et al. 1993).  E2F1-6 can dimerize 
with DP1-2 proteins in all possible combinations and act as potent activators for 
proliferation factors (Wu et al. 2001). 
K-cyclin, like other viral cyclins, is a cellular cyclin mimic made by KSHV to 
deregulate the host's cell cycle and impose its own control of cellular pathways.  The 
protein is expressed as a 5.32 kilobase transcript made in the latent phase of the virus and 
spliced to make three different proteins, ORF71 viral FLICE-like inhibitory protein (v-
 12
FLIP), ORF72 viral cyclin D mimic (K-cyclin), and ORF73 LANA (Figure 1, Kellam et 
al.1997, Dittmer et al. 1998, van Dyk et al 1999).  K-cyclin, shares thirty-one percent 
amino acid structure and fifty-three percent similarity with cellular D-type cyclins 
(Cannell et al. 1999).   While cyclin D2 binds to cdks 4 and 6, K-cyclin binds to those 
and additionally cdk2, cyclin E and A’s standard kinase partner (Jung et al. 1994, 
Godden-Kent et al. 1997, Li et al. 1997).  Cyclin D2 is inhibited by p21 and p27, while 
no cdk inhibitors by K-cyclin. For example, in the case of p27, its inhibition is interrupted 
by K-cyclin and its ability to phosphorylate p27's amino acids 10 and 187 and decrease 
overall protein stability (Figure 4, Swanton et al. 1997, Sarek et al. 2006). Cyclin D2 
furthermore, has only one known phosphorylation target, pRb, whereas K-cyclin’s 
phosphorylation targets include pRb, p27, histone H1, Bcl-2, inhibitor of DNA binding-2 
(Id2), cdc25a and p300 (Figure 4, Ojala et al. 2000, Laman et al. 2001, Sarek et al. 2006, 
unpublished data). While cellular cyclins/cdk complexes are regulated by the 
phosphorylation and activation by the cyclin activating kinase protein (CAK), K-cyclin is 
active even when not phosphorylated by CAK, making it less dependent on host-cell 
interactions for its activity (Child et al. 2001). Additionally, our studies in KSHV-
infected cells show that the half-life of K-cyclin is greater than that of cellular cyclin D2 
(half-life of ~6-8 hours vs. ~0.5 hours respectively). The decreased turnover of K-cyclin 
results in constitutive activation of K-cyclin/cdk6 complexes throughout the cell cycle.  
K-cyclin is both cytoplasmic and nuclear but most important, K-cyclin/cdk6 complexes 
are kinase active throughout the cell cycle (Figure 3, Davis et al. 1997, Van Dross et al. 
2005). This uncontrolled K-cyclin/cdk6 kinase activity may be essential for maintaining 
viral latency and ultimately, contribute to the oncogenic nature of KSHV. 
In addition to its work directly with cell cycle regulation proteins, K-cyclin also 
can directly trigger the initiation of DNA synthesis. K-cyclin /cdk6 complexes can 
phosphorylate Orc1, implicating K-cyclin in DNA replication and possibly licensing of 
the pre-replication complex (Figure 4, Laman et al. 2001).  The literature supports this 
finding in that cyclin A/cdk2 can interact with the ORC complex by recruiting it to the 
origin of replication (Xua et al. 1998). K-cyclin deregulates the cell cycle by regulating 
pRb at both cell checkpoints. 
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Figure 4. K-cyclin/cdk6 Complexes Interacting Partners and Phosphorylation Targets.  The 
figure is an illustration of some of the known K-cyclin interacting proteins and their implications 
in cell cycle, apoptosis, DNA replication and transcription.  In its role to deregulate cell cycle, K-
cyclin/cdk6 compleses can phosphorylate pRb, releasing E2F and advancing cells through the 
first cell cycle checkpoint and into S phase. Phosphorylation of p27 can stop its inhibitory effect 
on cell cycle and cause it to be degraded. Then, K-cyclin/cdk6 complexes can interact with the 
E2F binding site in and upregulating Cyclin A transcription, another promoting factor for S 
phase.  Additionally, phosphorylation target Orc1 is an integral part of licensing for DNA 
replication.  Bcl-2 is phosphorylated by K-cyclin/cdk6 complexes and inhibits the activation of 
the apoptotic pathway.  K-cyclin’s involvement in the transcriptional pathway, in addition to 
cyclin A, revolves around NF-κB and p300.  K-cyclin/cdk6 complexes can phosphorylate p300 
and by an unknown mechanism regulate the NF-κB transcription factor family.  This activation 
can upregulate survival factors like the D-type cyclins and anti-apoptotic genes like Bcl-xL.  
Finally, we have shown that K-cyclin can interact with LANA and we theorize that it modulates 
LANA’s role as a transcription factor. 
 
 
  As previously stated, K-cyclin/cdk complexes are not dependent on CAK 
activity and so are less regulated by mitogenic and other cellular factors. Although the 
mechanism by which K-cyclin affects mitotic exit is unknown, K-cyclin expressing cells 
continually undergo DNA synthesis and nuclear division but have problems with 
cytokenesis (Verschuren et al. 2002).  With its phosphorylation of pRb to bypass 
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checkpoints, no regulation from the cyclin dependant kinase inhibitors and constitutive 
activation throughout the cell cycle with at least cdk6, K-cyclin can continuously 
accelerate its host cell through the phases of the cycle influencing growth, proliferation, 
and replication.    
 
Implications in Transcription 
There is one published example of K-cyclin directly regulating the transcription 
of another protein, cyclin A. Although it does not phosphorylate pocket protein p107 or 
interact directly with E2F, transcription is facilitated through the E2F binding site in the 
cyclin A promoter and is dependent on cdk6 activity (Figure 4, Duro et al. 1999).  The 
similarities between K-cyclin and cellular cyclin/cdk complexes suggest that K-cyclin 
may be a transcriptional regulator in other cases as well.  Chromatin is a tightly packed 
complex of DNA with histone proteins that protect DNA. The expression of cellular 
genes is determined in part by the structural organization of DNA in the chromatin. Gene 
activation requires the unfolding of sections of chromatin to permit the binding of factors 
comprising the transcriptional machinery. This unfolding of chromatin allows for its 
separation into two types, euchromatin or that which is transcriptionally active, 
comprising ~5-10% of all DNA, and the rest unavailable for transcription, 
heterochromatin (Bloom, 1978). The euchromatin is depleted of histone H1 and is 
enriched in hyperacetylated core histones necessary for chromatin unfolding as well as 
transcriptional activators, transcriptional co-activator proteins such as p300/CBP and 
other histone acetyltransferase proteins, and the ATP-dependent chromatin remodeling 
proteins, BRG1 and Brm (Komaiko et al. 1985, Hebbes et al. 1988, Oliva et al. 1990, 
Boyes et al.1998, Goodman et al. 2000, Vignali et al. 2000). 
 
NF-κB-dependent Transcription 
 Studies show that the primary effusion lymphoma (PEL) cell lines and clinical 
KSHV infected PEL biopsy specimens contain constitutively activated NF-κB (Keller et 
al. 2000, Krug et al. 2007).  This activation is important in producing cytokines and is 
essential for establishing latency in KSHV infected cells (Libermann et al. 1990, 
Guasparri et al. 2004).  Furthermore, NF-κB target genes include anti-apoptotic genes 
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like Bcl-2 and Bcl-xL which ensure cell survival (Thome et al. 1997, Chaudhary et al. 
1999, Guasparri et al. 2004). Seventy percent of IL-6 expression can be attributed directly 
to v-FLIP, a major source of NF-κB activation (Chaudhary et al. 1999). But unpublished 
data from the Browning lab identified a novel substrate of K-cyclin/cdk6 complexes in 
KSHV-infected cells, the NF-κB transcriptional co-activator p300/CBP.   
The NF-κB protein family is a group of transcription factors that regulate the cell 
growth and survival, inflammatory and immune response.  The transcriptional activator’s 
target genes include IL-6, c-FLIP, Bcl-xL, Bcl-2, p53 and cyclins D1, D2 and D3 
(Libermann et al. 1990, Grimm et al. 1996,Wang et al. 1996, Zhong et al. 1998, Chen et 
al. 1999, Guttridge et al. 1999, Tsukahara et al.1999, Catz et al. 2001, Kruez et al. 2001, 
Huang et al. 2004, Schumn et al. 2006).  There are seven different NF-κB subunits: Rel 
A/p65, p105 and its splicing product, p50, p100 and its splicing product p52, c-Rel and 
Rel B that combine in a number of ways.  Rel A/p65, c-Rel, and Rel B, contain 
transactivation domains but p50 and p52 do not (Nabel et al. 1987, Libermann et al. 
1990, Beg et al. 1993).  Their common domain is a rel homology domain that can 
mediate DNA binding, dimerization and interaction with the IκB family of NF-κB 
inhibitors.  These nuclear factors are regulated by sequestration in the cytoplasm.  NF-κB 
is the product of a signaling cascade that results in the subunits’ translocation to the 
nucleus.  Once there, NF-κB subunits can interact with CBP/p300 to effect transcription 
(Figure 5, Nabel et al. 1987, Murcurio et al. 1992, Beg et al. 1993, Dallas et al. 1993, 
Kwok et al. 1994, 1996, Lill et al. 1997, Perkins et al 1997, Zhong et al. 2002). 
The ability of p300 to activate transcription is dependent on  its histone 
acetyltransferase (HAT) domain.  Acetylation of the histones associated to the promoter 
or other enhancer regions of the genes causes activation by chromatin remodeling. After 
remodeling it can recruit and assemble proteins like NF-κB, p53, c-myc, c-Jun, c-Fos and 
viral proteins E2F and Human Immunodefiency Virus (HIV) Tat (Bannister et al. 1995, 
Eckner et al. 1996, Ogryzko et al. 1996, Avantaggiati et al. 1997, Scholnick et al. 1997) 
One NF-κB subunit that interacts with p300 is p65, in an area separate from the one that 
interacts with cyclin/cdk complexes.  This interaction and subsequent acetylation 
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regulates the strength and length of time NF-κB is present in the nucleus (Perkins et al. 
1997, Goodman et al. 2000). 
  
 
 
 
 
Figure 5. NF-κB Signaling Cascade.  Extracellular ligands like epidermal growth factor (EGF) 
and platelet-derived growth factor (PDGF) can activate receptors along the cell surface and begin 
the MAP kinase, or AKT cytoplasmic signaling cascade.  The cascade finally winds up 
phosphorylating IKK-γ (NEMO) and releasing IκB kinase.  IκB kinase will then phosphorylate 
IκB and subsequently release the NF-κB subunits, in this case represented by p50 and p65.  Once 
they are released, the subunits transclocate to the nucleus.  There, the subunits join other co-
activators like p300 and binding to the NF-κB recognition element the DNA of their target genes. 
When their work is done, they will be ubiquitinated and degraded by the proteosome.  NF-κB is a 
crucial target for viral proteins due to its wide variety of target genes that include cytokines, anti-
apoptotic genes and survival factors. 
 
 
The interaction with p300 can have two effects.  The first is to bind with other 
proteins to specific DNA recognition elements and repress transcription.  For example, 
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repressing NF-κB (Park et al. 2007).  The second is to bind to p21WAF1/CIP1 at its 
CRD1 domain and de-repress or activate transcription (Snowden et al. 2000). Although 
K-cyclin is not inhibited by p21 WAF1/CIP1, it blocks the action of p21 by 
phosphorylating it on serine 130 (Jarviluoma et al. 2006).   This is an excellent example 
of how cell cycle proteins can influence the regulation of growth factors, stress response 
genes, cytokines, genes related to immunity, and other survival factors (Perkins et al. 
1997, Richmond 2002). Moreover, unpublished data from the Browning Lab shows that 
K-cyclin/cdk6 complexes can phosphorylate in vivo and in vitro transcribed and 
translated p300 and together with p300 synergistically activate NF-κB -dependent 
transcription.  These findings suggest that K-cyclin/cdk6 complexes could be a 
contributing factor for constitutive activation of NF-κB in KSHV-infected cells.  This 
activation may act in concert with LANA activation through the AP-1 response element 
to increase IL-6 (An et al. 2003).  Whether K-cyclin can interact in other parts of the 
signaling pathway in either the nucleus or cytoplasm is unknown. 
  K-cyclin contains a protein docking site near the amino terminus, termed the 
MRAIL motif.  This site, identified in cyclin A, allows cellular cyclins to interact with 
proteins containing RXL motifs, like cyclin A/cdk2 phosphorylation targets p107 and 
p130 (Schulman et al.1998).  Several cellular and viral cyclins have this conserved 
protein docking site (Table 1) which may mediate the selection, binding and subsequent 
phosphorylation of kinase substrates.  These corresponding proteins can be divided into 
two categories: those that are cell cycle related like the E2F proteins, p107, p130, p27, 
pRb (Table 3), DNA replication related Orc1, and Orc6 (Table 4) and those that are 
transcriptional regulators like p300, CBP, and P/CAF (Table 2, Wilmes et al. 2004).  The 
RXL motifs in p300 were of particular interest as we also identified potential 
phosphorylation sites that fit the sequence for cdk phosphorylation targets. At least one 
novel K-cyclin/cdk6 target, caldesmon-1, an actin and calmodulin binding protein, was 
identified phosphorylated at four serine/threonine and proline motifs.  Caldesmon is 
known to be phosphorylated by cdk1 in vivo, while this work shows that Cyclin A and 
E/cdk2 complexes can also phosphorylate it in vitro.  The caldesmon kinase-targeted 
sites, while similar, are not exactly the same for the different kinases. This suggests that 
there is another indicator for substrate specificity. Cuomo et al. proposes the 
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serine/threonine and then proline motif as the target for cdk6 (Cuomo et al. 2005).  
Subsequently, we have identified several serine/threonine proline motifs in potential 
interaction proteins (Tables 2B, 3B, 4B). Substantiating their theory, there are six Cy or 
RXL motifs and at least forty serine/threonine proline motifs in p300 and other K-cyclin 
potential interactors (Table 2A, 4A, 6A). 
 
 
Table 1. MRAIL motif is conserved in both Cellular and Viral Cyclins.  Acompliation 
of the N-terminal ends of viral and cellular cyclins, beginning atposition 50.  K-cyclin is 
produced by Kaposi’s Sarcoma Associated Herpesvirus.V-cyclin is herpesvirus saimiri, 
M-cyclin is murine herpesvirus 68. Cyclins D1,D2, D3, E and A are cellular. 
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Table 2. Potential Protein Binding and Phosphorylation Motifs in DNA replication 
Proteins. (A) A survey of the amino acid sequence of several DNA replication proteins 
show several RXL motifs that could act as binding sites to the corresponding MRAIL 
protein K-cyclin and its kinase partner, cdk6. (B) The same proteins when scanned for 
potential phosphorylation sites serine or threonine and proline. There are several sites in 
each protein that could be subject to phosphorylation by K-cyclin/cdk complexes or other 
kinases. These sites suggest that through the MRAIL-RXL motifs, K-cyclin may play a 
role in DNA replication. 
 
 
A
  
 
 
 
 
 
 
 
 
 
 
 
 
B
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Table 3. Potential Protein Binding and Phosphorylation Motifs in Transcriptional 
Regulators. (A) A survey of the amino acid sequence of several NF-⎢B subunits show 
several RXL motifs that could act as binding sites to the corresponding MRAIL protein 
K-cyclin and its kinase partner, cdk6. Three proteins p100 and its splice variant, p52 and 
Rel-B do not have RXL proteins. The NF-⎢B subunits act as a pair though, so interaction 
with only one subunit may be necessary. At least one of those proteins p52, does not have 
a DNA- binding domain and so must bind with another subunit that contains one. (B) The 
same proteins when scanned for potential phosphorylation sites serine or threonine and 
proline. There are several sites in each protein that can be subject to phosphorylation by 
K-cyclin/cdk complexes or other kinases. These sites suggest that through the 
MRAILRXL motifs, K-cyclin could interact and activate NF-⎢B activation. 
 
 
A
  
 
 
 
 
 
 
 
 
 
 
 
 
 
B
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Table 4. Potential Protein Binding and Phosphorylation Motifs in Cell Cycle 
Proteins. (A) A survey of the amino acid sequence of several cell cycle proteins show 
several RXL motifs that could act as binding sites to the corresponding MRAIL protein 
K-cyclin and its kinas partner, cdk6. (B) The same proteins when scanned for potential 
phosphorylation sites serine or threonine and proline. There are several sites in each 
protein that could be subject to phosphorylation by K-cyclin/cdk complexes or other 
kinases. These sites suggest that through the MRAIL-RXL motifs, K-cyclin could 
influence cell cycle in other ways. 
 
 
A
  
 
 
 
 
 
 
 
 
 
 
 
 
B
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Cyclins as Transcriptional Regulators 
Cellular cyclins, in addition to their main function, have emerging roles in the 
transcriptional regulation of proteins as well. Cyclin D1 is recruited to the p21WAF1 
promoter by the STAT3-NcoA complex.  This interaction hinders the recruitment of CBP 
and RNA polymerase II, thereby inhibiting p21 transcription (Bienvenu et al. 2005). 
Cyclin D1 also binds to the histone acetyltransferase, p300/CREB-binding protein-
associated protein (P/CAF) to potentiate its activity with the estrogen receptor and affect 
its downstream targets (McMahon et al. 1999).  Cyclin E can associate with the androgen 
receptor and mediate its activity with the association of cdk2 (Yamamoto et al. 2000).  
Cyclin A can interact with and phosphorylate Sp1 in a promoter specific fashion (Fojas 
de Borja et al. 2001, Haidweger et al. 2001).   Finally, cyclins E and A can both regulate 
transcription when tethered to the LexA DNA-binding protein.  They have opposite 
actions though, with cyclin E activating and cyclin A repressing transcription (Rottman et 
al. 2005, Santaguida et al. 2005).  
Viral cyclins, too, have been shown to be involved in transcriptional regulation.  
The walleye fish retroviral cyclin, which shares 13% identity and 24% similarity with K-
cyclin (LaPierre et al. 1999), has been shown to regulate gene expression through its 
interactions with RNA pol II and the Mediator complex (Quackenbush et al. 1997).  
MHV68 cyclin has been shown to have oncogenic properties through its ability to 
regulate T-cell development and cell cycle progression (van Dyk et al. 2000). Therefore, 
it is quite feasible that K-cyclin may behave in a similar manner as other viral cyclins in 
tumor development. 
 
Hypothesis 
Summarized here are unpublished data that suggest that K-cyclin is a transcription 
factor.  First, the Browning lab has shown that K-cyclin associates with the 
transcriptionally active S1 fraction of chromatin along with other proteins like p300, 
polymerase II and transcription factor IID (TFIID) known to be involved in transcription. 
Second, in vitro kinase assays using K-cyclin and cdk6 proteins from transfected SF9 
cells shows that these complexes can phosphorylate p300. Furthermore, we have 
identified protein-docking sites available in both K-cyclin and p300 that could mediate an 
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association between the proteins and p300 putative phosphorylation sites.  Next, K-cyclin 
has been shown to activate NF-κB dependent transcription in reporter assays, is 
synergistic with p300 and is cdk dependent.  Lastly, we have identified a novel 
association between K-cyclin and LANA, a multifunctional viral protein involved in 
transcription by interacting directly with DNA and through protein-protein interactions 
with other transcription factors like AP-1, Sp1 and pRb.  These findings suggest that K-
cyclin is a transcriptional regulator and that these may play a role in the signature NF-κB 
activation found in KSHV-infected cells. 
 
Overview 
In this work, we present the data that K-cyclin/cdk6 kinase complexes regulate 
NF-κB-dependent gene expression and this activation can be impeded by mutation of the 
MRAIL protein docking site in K-cyclin.  As K-cyclin and LANA are both transcribed 
from a single promoter, are expressed at the same time in the viral life cycle and are both 
found in the nucleus, we sought to determine whether they physically interact. We show a 
novel association between K-cyclin and LANA, two viral proteins that interact in a 
protein complex exclusive of other viral proteins. These results suggest that K-cyclin-
modulated kinases regulate transcription outside of the realm of the cell cycle, and that 
activation of the NF-κB pathway may contribute to the abnormal proliferative properties 
of KSHV-infected cells.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Plasmids 
K-cyclin and the fusion protein consisting of the DNA binding domain of the 
yeast transactivator, GAL4 BD-K-cyclin were subcloned into the eukaryotic expression 
vector, pBKCMV by PCR. Stephen Brandt (Vanderbilt University, TN) provided the 
p300 expression plasmid, pCDNA3-p300. The dominant negative p300 plasmid was 
provided by Antonio Giordano (Thomas Jefferson University, Philadelphia, PA), and 
Jennifer Pietenpol (Vanderbilt University, Nashville, TN) kindly provided the luciferase 
reporter minimal promoter containing the TATA element. The NF-κB responsive 
plasmid NF-κB-Luc was obtained from Stratagene (La Jolla, CA). Dominant negative 
cdk6 was a kind gift from Charles Sherr (St. Jude Children’s Hospital, Memphis, TN). 
pcDNA 3.1 LANA was the kind gifts of Rolf Renne (University of Florida, Gainesville, 
FL). 
 The K-cyclin MRAIL mutants were generated as instructed by the manufacturer 
with the Quickchange XL kit Stratagene (La Jolla, CA). The following primers were used 
in a PCR reaction to change the final two bases of the specified codon. M50A 
5’GCCCAGTAACTTACGCGCATGCGAAGTAAGAGA3’ 3’TCTCTTACTTCG 
CATGCGCGTAAGTTACTGGCG5’ 50,54A 5’ TCTCTTACTTCGCATGCGCG 
TAAGTTAGCGGGCACATGGATGTTT 3’AAACATCCATGTGCCCGCTAACT 
TACGCGCATGCGAAGTAAGAGA 50, 54, 57A 5’TCTCTTACTTCGCA 
TGCGCGTAAGTTAGCGGGCACAGCGATGTTTTCAGTTTGC 3’GCAAACTGAAA 
ACATCGCTGTGCCCGCTAACTTACGCGCATGCGAAGTAAAGA. 
 
Reagents 
Sheep K-cyclin and sheep immunoglobulin G (IgG) antibodies were developed at 
Exalpha Biologicals, Inc. (Watertown, MA).  Antibodies to LANA (product 13-210-100) 
were obtained from Applied Biologicals, Inc. and cdk6 (product C-21), orc1 (product H-
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60) and cdc6 (product H-304) were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA).  Aprotinin, leupeptin, pepstatin A, DNase A and PMSF were from Sigma (St. 
Louis, MO).  All other reagents in this study were reagent grade. 
 
Cell Culture and Transfections 
Primary Effusion Lymphoma (PEL) cell line (BC3) is KSHV-containing human 
cells.  They were obtained from American Tissue Cell Culture (ATCC, Manassas, VA) 
and maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum (Hyclone, Logan, UT), sodium pyruvate, penicillin (100U/ml) 
and streptomycin (100ug/ml) Epstein-Barr virus positive, KSHV-negative Daudi cells 
were obtained from ATCC and maintained in RPMI 1640 medium.  Cos-7L and 293H 
cells were obtained from ATCC and maintained in Dulbecco’s Modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 0.1mM non-essential amino acids 
(Mediatech, Herndon, VA), penicillin (100U/ml, Invitrogen), streptomycin (100ug/ml, 
Invitrogen), 2.5 M HEPES (Mediatech) and 2 M glutamine (Invitrogen). Cos-7L cells 
were transfected at 2.1x 106 with Lipofectamine 2000 (Invitrogen) or calcium phosphate 
in 10cm2 dishes and were assayed for protein expression. Luciferase assays were 
performed using the Dual Luciferase Reporter Assay System (Promega, Madison, WI). 
Each experiment was performed in triplicate and each experiment independently 
performed at least three times.  
 
In Vitro Transcription and Translation 
In Vitro transcription and translation was performed according to the protocol by 
the TNT T7 and S6 Quick Coupled Transcription and Translation Reticulocyte System 
(Promega, Madison, WI). 1 ug of pBKCMV-K-cyclin DNA template with the indicated 
mutation was combined with prepared rabbit reticulocyte lysate, TNT reaction buffer, 
1mM amino acid mixture without methionine, 40 units of RNAsin, the supplied Rnase 
inhibitor, nuclease- free water, T7 RNA polymerase and 35S methionine with 
approximately 1 millicurie of radioactivity.  The reaction was incubated at 30o degrees 
for 60 minutes.  One-fifth of the product was run on a 10% SDS-PAGE gel for resolution, 
gel dried and exposed to x-ray film at -80oC for 2 hours. 
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Immunoprecipitations 
BC3 or Cos-7L cells were lysed by manipulation with a 23 gauge needle four 
times in kinase lysis buffer (KLB) (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 0.1% Triton 
X100, 0.1% NP-40, 4 mM EDTA, 4 mM NaF, 0.1 mM sodium orthovanadate, 0.1% 
BSA, 1 mM PMSF, 2 μg/ml aprotinin, and 2 μg/ml leupeptin), or radio 
immunoprecipitation assay (RIPA) buffer (0.5M TRIS-HCl, pH7,4 1.5M NaCl, 2,5% 
deoxycholic acid, 10% NP-40, 10mM EDTA, 1mM PMSF, 1 ug/ml leupeptin, 1 μg /ml 
pepstatin A, 1 μg /ml apoprotin). All antibodies for immunoprecipitation were conjugated 
to protein G Sepharose beads (Amersham-Pharmacia, Piscataway, NJ). Cell lysates or 
chromatin fractions were pre-incubated with sheep IgG (Santa Cruz Biotechnologies, 
Santa Cruz, CA) for 1 hr at 40C and centrifuged. The cell lysates were centrifuged at 
10,000g for thirty seconds, and the supernatant was transferred to a clean microfuge tube. 
The supernatants were incubated with the selected antibody overnight at 40C. The beads 
were washed three times with KLB or RIPA lysis buffer, and the buffer was discarded. 
The beads were resuspended in an equal volume of 4x NuPAGE LDS–loading dye 
(Invitrogen), heated for 10 minutes at 70oC, and resolved using 10% SDS-PAGE.  
 
Immunoblots 
Proteins resolved by SDS–PAGE were transferred to Immobilon P membranes as 
instructed by the manufacturer (Millipore, Bedford, MA). The membrane was then 
incubated in a solution of TRIS-buffered saline and Tween-20 (TTBS = 0.02 M TRIS–
HCl [pH 7.6], 0.14 M NaCl, and 0.05% Tween-20) blocking buffer (Sigma, St. Louis, 
MO) at room temperature for 1 hour. The membrane was incubated with antibodies 
against K-cyclin, at a 1:20,000 dilution in TTBS and Sigma blocking buffer. Membranes 
were then washed five times in TTBS and incubated with the appropriate secondary 
antibody (Amersham Biosciences Piscataway, NJ) at a 1: 10,000 dilution for 1 hour in 
TTBS with Sigma blocking buffer. After five 5-minute washes in TTBS, the membrane 
was incubated with enhanced chemiluminescence (Supersignal; Pierce) for five minutes, 
as described in the instruction manual. To visualize western blot protein bands, the 
membranes were exposed to x-ray film at room temperature and developed in a film 
processor.  
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Primary antibodies probes with LANA (rat monoclonal 1:1,000, ABI) were 
conducted overnight at 4o, and cdk6 C-21 (mouse monoclonal 1:15,000, Santa Cruz), 
Orc1 H-60 (rabbit polyclonal 1:1,000), cdc6 H-304 (rabbit polyclonal 1:1000) for sixty 
minutes at room temperature followed by incubation with appropriate horseradish 
peroxide-conjugated secondary antibodies (Amersham). Transfer and immunodetection 
were performed as described above.  
 
Nuclear and Cytoplasmic Cell Fractionation 
 Cytoplasmic extracts were prepared by washing 1 x 108 BC3 cells in PBS, 
centrifuging cells as described above, and resuspending the cell pellet in nuclear 
separation media (10 mM TRIS–HCl [pH 7.5], 25 µM sodium fluoride, 5 mM 
magnesium chloride, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM sodium vanadate, 
aprotinin at 5 µg/mL, leupeptin at 5 µg/mL, pepstatin at 5 µg/mL, and Pefabloc at 150 
µg/mL). Cells were allowed to swell on ice for 15 minutes and then homogenized in a 
dounce homogenizer with 20 strokes of pestle B. Nuclear material was removed from the 
cytoplasmic extract by centrifugation at 500g for 10 minutes at 4 °C, and the supernatant 
was further purified by centrifugation at 315,000g for 30 minutes. The supernatant from 
this centrifugation was the cytoplasmic lysate. Nuclear lysates were prepared from nuclei 
purified by sucrose gradient centrifugation. In brief, 1 x 108 BC3 cells were washed in 
PBS and resuspended in 4 mL of ice-cold sucrose buffer A (0.32 M sucrose, 3 mM 
calcium chloride, 2 mM magnesium acetate, 0.1 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, 0.1% Tween-20, 10 mM TRIS [pH 8.0], 0.1 mM sodium vanadate, aprotinin at 5 
µg/mL, leupeptin at 5 µg/mL, pepstatin at 5 µg/mL, and Pefabloc at 150 µg/mL). Cells 
were transferred to a dounce homogenizer and broken with 6 strokes of pestle B.  
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CHAPTER III 
  
RESULTS 
 
K-cyclin Can Activate NF-κB-dependent Transcription 
CyclinE/cdk2 and p300 assemble on NF-κB responsive genes and inhibit its 
transcriptional activity (Perkins et al. 1997). Additionally, inhibition of NF-κB regulated 
gene activity in multiple KSHV infected cell lines leads to apoptosis (Keller et al. 2000). 
Browning lab unpublished data suggest that K-cyclin can activate NF-κB dependent 
transcription in a dose-dependent manner, and we sought to duplicate that result.  To 
assess the effect of K-cyclin on the transcriptional activity of NF-κB, we used transient 
transfection with a model NF-κB responsive reporter gene, NF-κB-Luc, containing five 
NF-κB consensus binding motifs. NF-κB Luc was cotransfected with pBKCMV/K-cyclin 
or the corresponding empty vector into the 293H cells. As previously shown, K-cyclin 
induced transcription of the NF-κB reporter construct. The constructs were co-transfected 
with a control reporter construct containing only a minimal promoter region, TATA-Luc.  
The K-cyclin-mediated transcriptional enhancement was abolished in cells containing the 
MRAIL mutants.  The fold activation over that of control pBKCMV was approximately 
seventeen units above the baseline (Figure 6). These data suggest that K-cyclin induces 
transcription specifically through the NF-κB DNA binding consensus sequence. 
 
MRAIL Mutants Can Be Translated into Full Length K-cyclin Protein 
The MRAIL motif is a conserved protein-docking site in the N-terminus of both 
cellular and viral cyclins (Table 1). Its corresponding site is present in several proteins, 
including p105 and its splice product p50, c-Rel, Rel-B and p300 (Table 2A) in addition 
to putative phosphorylation sites (Table 2B). To determine whether the MRAIL-RXL 
interaction was essential for activation of NF-κB dependent transcription, we first 
generated single amino acid mutants of K-cyclin’s MRAIL motif.  We produced oligos 
matching K-cyclin’s nucleotide sequence that included a wobble codon at the appropriate 
site.  Using PCR and site-directed mutagenesis, we generated alanine mutants of the 
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amino acid residues comprising the MRAIL motif.  This allowed a change in the amino 
acids deemed most important for compromise of the MRAIL protein-docking site, 
position 50’s methionine, 51’s arginine, 53’s leucine and 57’s tryptophan.  In addition, 
we generated a mutant with a double alanine mutation at positions 50 and 54 and a triple 
mutant at position 50, 54 and 57. To characterize each mutant, each plasmid was 
sequenced for verification of the mutation and then the protein was in vitro transcribed 
and translated (Figure 7). We were able to show that each protein though mutated did 
produce full-length protein similar to that of wild type K-cyclin. 
 
MRAIL Protein Docking Site Mediates K-cyclin Activation of NF-κB-
dependent Transcription 
 
To assess the effect of the MRAIL docking site on NF-κB dependent 
transcription, we co-transfected the NF-κB-Luciferase plasmid along with pBKCMV K-
cyclin plasmid, into 293H cells.  We were able to show that each mutant in a step-wise 
manner was sufficient to decrease the K-cyclin affect on the reporter construct. We graph 
these results next to the control plasmid and the previously shown wild-type K-cyclin 
affect.    We were able to show an approximately seventeen-fold difference between K-
cyclin and a mutant containing even one alanine in the MRAIL protein docking site.  
Furthermore, we show that there is not an additive affect with a further mutagenesis of 
the protein-docking site in the form of a double or triple mutant (Figure 8).  These data 
suggest that K-cyclin’s MRAIL motif mediates its effect on NF-κB dependent 
transcription. 
 
LANA and K-cyclin Bind in KSHV-infected Cells 
While its primary role involves episomal maintenance, LANA also functions as a 
transcriptional regulator in a variety of cellular and viral promoters, including its own 
(Lim et al. 2001, Renne et al. 2001, Garber et al. 2002, Verma et al. 2004). As K-cyclin 
and LANA are both transcribed from a single promoter, are expressed at the same time in 
the viral life cycle and are both found in the nucleus, we sought to determine whether 
they physically interact. Because both proteins are nuclear, the logical step was to extract 
the BC3 nuclei and look for an association. Using the nuclear lysate from BC3 cells 
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infected with KSHV, we used K-cyclin to immunoprecipitate a fraction of nuclear LANA 
at endogenous levels (Figure 9).  Additionally, the fraction of LANA that associates with 
K-cyclin, in addition to being nuclear, is also akin to the fraction of LANA with the 
greatest amount of post-translational modifications compared to the total LANA available 
in the cell (Figure 9, lane 1).  
 
LANA and K-cyclin Bind in Transfected Cos-7L Cells 
The association between K-cyclin and LANA was shown at endogenous levels in 
KSHV infected BC3 cells.   Because we do not have data to suggest that these proteins 
directly bind, we must investigate the nature of this association.  To determine if this 
association requires other viral proteins, we expressed both proteins in a non-virally 
infected cell line, Cos-7L.  By transfecting pcDNA 3.1 LANA and pBKCMV K-cyclin 
into Cos-7L cells, we were able to get expression of both proteins (Figure 10A).  Again 
using K-cyclin as bait, we were able to immunoprecipitate LANA from whole cell lysate 
(Figure 10B).  These data suggest that the K-cyclin and LANA complex may require 
other proteins to interact, but they are not viral in origin. 
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Figure 6. K-cyclin Can Activate NF-kB Dependent Transcription. (A) Kcyclin’s 
action on the NF-kB recognition element was assessed by reporter assay. 
The reporter plasmid contained five copies of the NF-kB recognition element in sequence 
along with a promoter tied to a luciferase gene. (B) pBKCMV, an empty vector, was 
compared to pBKCMV-K-cyclin, to determine whether the expression of the reporter 
gene was upregulated. When K-cyclin is present, NFkB- dependent transcription was 
increased approximately seventeen fold over the vector alone. 
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Figure 7. MRAIL Mutations Make Full Length K-cyclin Protein. To investigate the 
role of the MRAIL motif in K-cyclin activation of NF-⎢Bdependent transcription, we 
made mutations in the proteins. At position 50, the methionine was changed to alanine 
(K- cyclin M50A). We added a change of leucine at position 54 to the original 
methionine to alanine mutation and created a double mutant (K-cyclin 50, 54A). Finally, 
the tryptophan at position 57 was changed to alanine to create a triple mutant (K-cyclin 
50, 54, 57A). Each of the proteins were in vitro transcribed and translated, to ensure that 
the mutations did not compromise the protein expression. We found that each of the 
proteins were expressed at the same level regardless of mutation. 
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Figure 8. MRAIL Mutants Reduce K-cyclin Activation of NF-⎢B-Dependent 
Transcription. Based on the earlier findings that K-cyclin activated NF-⎢Bdependent 
transcription, we used the same assay to determine whether the MRAIL motif was 
important in this activation. We were able to show that Kcyclin activation was 
significantly higher than the empty vector (pBKCMV). Furthermore, when the K-cyclin 
mutants were added, each one reduced the activation over ten-fold. Additionally, there 
was no additive effect given by the double or triple mutants. 
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Figure 9. K-cyclin Can Immunoprecipitate LANA from BC3 cells. BC3 cells are a 
KSHV infected B cell line. Lane 1 shows the amount of LANA in BC3 cells. Lane 2 
shows the amount of LANA available in BC3 nuclei. LANA can be immunoprecipitated 
by K-cyclin from BC3 cells as evidenced in lane 4. 
 
 
 
 
 
Figure 10. LANA and K-cyclin, When Expressed in Cos-7L cells Physically Interact. 
(A) pcDNA 3.1 LANA and pBKCMV K-cyclin were transfected into Cos-7L cells. The 
top panel is lysate (as labeled) probed with LANA antibody. The bottom panel is a 
western blot showing K-cyclin expression. The positive control is lane 1, BC3 whole cell 
lysate and the negative is lane 2, daudi cell lysate. (B) The transfected lysate was 
immunoprecipitated with K-cyclin and then probed for LANA. LANA and K-cyclin can 
co-immunoprecipitate in non-virally infected cells and without the expression of any 
other viral proteins. Lane 1 is BC3 whole cell lysate and lanes 2 and 3 are transfected 
Cos-7L lysate immunoprecipitated with sheep IgG and sheep K-cyclin antibody 
respectively. 
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CHAPTER IV 
 
DISCUSSION 
 
Introduction 
Cellular and viral cyclins are emerging as multifunctional proteins.  In addition to 
their roles as cell cycle regulators, data show that cyclin E, for example, is directly 
involved in transcription and licensing for DNA replication through its protein-protein 
interactions.  In this case, K-cyclin, a viral cyclin mimic, is characterized by its unique 
protein-protein interactions including partnering with cdks 2, 4 and 6 (Godden-Kent et. al 
1997). The literature provides definite evidence that K-cyclin is involved in cell cycle 
deregulation, evading apoptosis and DNA replication in addition to suggestive evidence 
and implications that it may play a role in transcription (Figure 4).   The initial 
observation that K-cyclin associated with transcriptionally active chromatin opened a 
new realm of possibilities for a viral cyclin.  The follow-up experiments with K-
cyclin/cdk6 being constitutively active throughout the cell cycle and phosphorylating 
p300 correlate with the other data and suggest that K-cyclin may be implicated in 
transcription (Figure 4, Van Dross et al. 2005, unpublished data). Unpublished data from 
the Browning lab showed that K-cyclin could activate NF-κB dependent transcription, 
and we repeated those results in this report (Figure 6). The experiments discussed here 
look at the role of K-cyclin in one signaling cascade that p300 is a part of, NF-κB. Cyclin 
E binds to p300 within the carboxyl terminus only if complexed with cdk2 and if derived 
from a cellular source (Perkins et al. 1997). In contrast, our unpublished data shows that 
K-cyclin binds to p300 in the absence of cdk6, whether generated by in vitro 
transcription/translation or in bacteria. Moreover, because K-cyclin binds across multiple 
p300 epitopes, these regions could be in turn rendered susceptible to phosphorylation by 
K-cyclin/cdk6 complexes. Furthermore, phosphorylation of p300 may affect the binding 
of other transcriptional co-activator proteins required to activate NF-κB-dependent 
transcription.   
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MRAIL Protein Docking Site Mediates K-cyclin NF-κB Activation 
Our studies sought to address the role of K-cyclin’s protein-protein interactions on 
its non cell cycle related function.  The work was based on our unpublished results that 
K-cyclin associates with the transcriptionally active fraction of chromatin and 
phosphorylates in vivo and in vitro transcribed and translated p300.  Our data shows that 
K-cyclin can activate a reporter plasmid with an NF-κB DNA recognition element 
(Figure 6). In seeking a protein docking site to facilitate this interaction, we identified the 
MRAIL and RXL sites described by Schulman et al. whereby cdk2 recruits substrates 
through Cyclin A.  We found that K-cyclin in addition to other cellular and viral cyclins 
contained this MRAIL motif in their N-terminal ends (Table 1). 
Although our experiments have not yet elucidated the mechanism of this activation, 
there are two main possibilities. We know that K-cyclin is both nuclear and cytoplasmic, 
K-cyclin could be directly binding to the NF-κB sequence in DNA. On the other hand, K-
cyclin/cdk6 complexes could phosphorylate proteins in the NF-κB signaling cascade 
(Figure 5, Van Dross et al 2005).  These protein-protein interactions could happen with 
any proteins including p300. The p300 repressor domain, CRD1, is shown to be a 
mechanism for p300 to facilitate repression (Figure 2, Snowden et al. 2000). The cdk 
inhibitor, p21CIP/Waf1, binds to this p300 domain and reportedly activates by de-
repression the NF-κB-dependent transcription. Although K-cyclin/cdk6 complexes are 
not inhibited by p21CIP/Waf1 in vitro and do not contain p21CIP/Waf1 in K-cyclin/cdk6 
complexes derived from KSHV-infected cells, it is conceivable that phosphorylation of 
p300 by K-cyclin/cdk6 complexes could enhance p21CIP/Waf1 binding to the repressive 
domain. This binding would have the effect of enhancing NF-κB-dependent transcription. 
Our data suggest that K-cyclin activation of the NF-κB reporter is increased with the 
addition of exogenous p300, information we believe strongly supports this mechanism. 
Several studies suggest that the cyclin subunit determines the substrate specificity 
of cyclin/cdk complexes. Studies evaluating how cyclin subunits determine substrate 
specificity using cyclins A and E suggest that important substrate binding regions reside 
in the carboxyl terminus of these cyclin proteins. We have identified a conserved 
sequence in the amino terminus of both cellular and viral cyclins that we believe is 
important in protein binding and subsequent phosphorylation (Table 1).  This seven 
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amino acid sequence termed the MRAIL motif, has been shown to be important in 
substrate selection by cyclin A for its cdk2 kinase partner (Schulman et al. 1998).  
Additionally, a motif that may be important for phosphorylation by cdk6, a serine or 
threonine followed by a proline, has been identified in the K-cyclin/cdk6 kinase target, 
caldesmon (Cuomo et al. 2005).  With all the potential docking and phosphorylation sites 
identified in proteins in the NF-κB cascade, we performed a mutational analysis to assess 
the role of K-cyclin’s MRAIL motif on its ability to activate NF-κB. We have identified 
several proteins that coincide with K-cyclin’s previously known or functions that contain 
these sites.  This protein docking site may be important in binding and potential 
phosphorylation of K-cyclin target systems, cell cycle (Table 3) and DNA replication 
(Table 4). We sought to determine whether the MRAIL-RXL interaction was essential 
for activation of NF-κB dependent transcription. We have identified many NF-κB 
transcriptional regulators that have RXL motifs and potential phosphorylation sites 
(Table 2). There were at least two NF-κB subunits that did not contain RXL motifs. We 
believe that this is insignificant as NF-κB subunits act as a unit on DNA. 
This data in concert with our observation that K-cyclin/cdk 6 complexes can activate 
NF-κB dependent transcription, led to the results reported here.  The amino acids selected 
for mutation, the methionine at position 50, the leucine at position 54 and the tryptophan 
at position 57 were selected as they were the most important in the interaction between 
cyclin A and p107 (Schulman et al. 1998).  We made K-cyclin mutants that contained 
mutations at position 50, a double mutant at positions 50 and 54 and finally a triple 
mutant with alanine substitutions at positions 50, 54, and 57.  We were able to show that 
even with these mutations, the sequences created full-length protein (Figure 7).   We 
found that the mutation of any single amino acid in the MRAIL motif is sufficient to 
disrupt the ability of K-cyclin to activate NF-κB luciferase reporter assay (Figure 8). One 
mutation alone was enough to significantly reduce NF-κB activation, with a double and 
triple mutation showing no additive effect.  Mutagenesis of this MRAIL docking site may 
inhibit binding of the K-cyclin/cdk6 complex to its kinase target p300, thereby reducing 
its effect on activation of the reporter gene.  Perkins et al. points out that the CRD1 
binding motif of p300, can bind p21, in a distinct and different domain than the region 
where p300 binds to cyclin E/cdk2 complexes (Perkins et al. 1997).  Consequently, the 
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K-cyclin MRAIL mutants, when bound, would not affect the ability of p21 to bind to 
p300.   This cannot explain the reduction in NF-κB activation. Furthermore, p21 is an 
RXL protein that K-cyclin phosphorylates to bypass a G1 cell cycle arrest, and an affect 
on p21 could be the mechanism of repression (Jarviluoma et al. 2006). 
 
NF-κB Activation By KSHV Latent Proteins 
Keller et al. show that the PEL cell lines and clinical KSHV-infected PEL biopsy 
specimens contain constitutively activated NF-κB (Keller et al. 2000). Moreover, 
activated NF-κB appears to be essential for PEL cell survival because inhibition of this 
pathway results in apoptosis (Keller et al. 2000). v-FLIP uses NF-κB to block apoptosis 
by inhibiting the association of FADD and pro-caspases 8 and 10 (Thome et al. 1997). 
But, K-cyclin too can inactivate apoptosis through its phosphorylation of Bcl-2 (Ojala et 
al. 2000). While v-FLIP is an effective activator of NF-κB dependent transcription, it is 
only responsible for seventy percent of the activation associated with IL-6 (Guasparri et 
al. 2004). The three important latent gene products represent likely viral candidate genes 
that may constitutively activate the NF-κB pathway. LANA and v-FLIP have both been 
shown to activate IL-6 through interacting with NF-κB and AP-1 (An et al. 2002, 2003). 
A reasonable hypothesis based upon these findings is that KSHV-encoded gene products, 
including K-cyclin, LANA and v-FLIP, may be responsible for the constitutive NF-κB 
activation found in KSHV cell lines and biopsy specimens. 
 
LANA and K-cyclin Bind in Both Viral and Non-Virally Infected Cells 
Furthermore, because of the similarity in expression and implications for function, 
we questioned whether there was a further relatedness between the latent proteins. As K-
cyclin and LANA are both transcribed from a single promoter, are expressed at the same 
time in the viral life cycle and are both found in the nucleus, we sought to determine 
whether they physically interact.  By using both virally infected BC3 and transfected non-
virally infected cells, we were able to show that K-cyclin associates with LANA in a 
complex that does not require any other viral proteins (Figure 9 and 10B).  
We believe that the binding of these two proteins occurs to modulate one of their 
functions. While LANA does play a role in episomal maintenance, there is no literature to 
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support a role for K-cyclin in this process. LANA also functions as an inducer of DNA 
replication.  In the TR region, there are two binding sites (LBS1/2), and when LANA is 
dimerized, it can occupy both (Fejer et al. 2003). When bound, a single LANA can bend 
DNA towards the major groove at approximately 57 degrees and when two bind, can 
bend it, at approximately 110 degrees (Wong et al 2005). In addition, K-cyclin 
phosphorylates Orc 1, a protein necessary for the formation of the pre-initiation complex.  
All of the Orc proteins (Orc1-6) can interact with LANA binding sequences in the TR 
region of the viral DNA.  The interaction between the viral DNA and Orcs 1, 3, 4 and 5 
are dependent on LANA’s presence.  With this in mind, we questioned whether the 
presence of K-cyclin could modulate LANA’s affect on DNA replication but were unable 
to show a significant outcome (data not shown).  The interaction between K-cyclin and 
LANA could suggest that LANA plays a role in cell cycle regulation.  LANA can interact 
with proteins in the pRb/E2F pathway to stimulate cyclin E expression and protect cells 
from p16 INK4a induced cell arrest (An et al. 2005). It also can interact with β-catenin to 
influence the transcriptional action of GSK-3β (Fujimoro et al. 2005).  LANA can also 
dramatically inhibit the transcriptional effect of p53 (Fribourg et al. 1999). But most of 
LANA’s effect is through its role as a transcriptional regulator. 
LANA has two mechanisms for regulating transcription: by binding to other 
transcription factors, or binding directly to DNA.   LANA can bind to both c-Jun and Sp1 
proteins to activate transcription of IL-6 and hTERT (An et al. 2002).  On the other hand, 
LANA’s DNA binding ability is shown when it regulates the viral promoter at the GC 
box/Sp1 recognition element despite the presence of DPE and TATA elements (Garber et 
al. 2001, Jeong et al. 2004). There is one published example of K-cyclin directly 
regulating the transcription of another protein, cyclin A. Although it does not 
phosphorylate pocket protein p107 or interact directly with E2F, transcription is 
facilitated through the E2F binding site in the cyclin A promoter and is dependent on 
cdk6 activity. 
 Because the proteins are made as a part of the same transcript, it is important to 
note that K-cyclin would also be present in the nucleus during LANA’s transcriptional 
work.  Furthermore, because these proteins were previously not known to associate, it is 
not surprising that it was never investigated as a part of these tasks.  Since the Browning 
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lab was one of the first to consider a possible role for K-cyclin as a direct transcriptional 
regulator, it is possible that K-cyclin or K-cyclin/cdk complexes are involved in one or 
more of these cases.  K-cyclin’s primary role is to deregulate the infected cell’s cycle, 
and regulating may be an additional mechanism to accomplish that goal. By binding to 
BRD4, LANA can regulate cyclin E transcription and release cells from a p16 induced 
G1 arrest (Ottinger et al. 2006).  Further investigation into K-cyclin target genes could 
reveal that is a part of regulating the transcription of cell cycle regulators. 
 
Conclusion 
The NF-κB pathway is well-known for its role in transcriptional activation of 
several cytokine related genes, such as tumor necrosis factor (TNF)α, TNFβ, interleukin 
(IL)-1, IL-2, IL-6, and IL- 8 (Richmond, 2002). Therefore, the NF-κB-activating ability 
of K-cyclin/cdk6 complexes may have important implications for the natural history of 
KS and PEL. One of the unique features of Kaposi's sarcoma is the involvement of 
cytokines and growth factors in the autocrine and paracrine growth (Swanton et al. 1997). 
The constitutive kinase activity of K-cyclin/cdk6 complexes likely contribute to this 
activity. The findings described here strengthen the view that gammaherpesvirus-encoded 
cyclins and K-cyclin in particular, have broader functions than overcoming the cell cycle 
block and may function as transcriptional regulators. Therefore, we propose that chronic 
activation of the NF-κB-dependent transcriptional pathway by the KSHV latent gene 
products including LANA, K-cyclin and v-FLIP, may contribute to establishing latency, 
blocking apoptosis and the abnormal proliferative properties of KSHV-infected cells 
comprising tumors such as primary effusion lymphoma and Kaposi’s sarcoma. Moreover, 
such chronic activation would set the stage for other genetic events that may ultimately 
result in cell transformation. 
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